Xi Liu1, Min Zhang2, Songmin Ying3, Chong Zhang1, Runhua Lin1, Jiaxuan Zheng1, Guohong Zhang1, Dongping Tian1, Yi Guo4, Caiwen Du4, Yuping Chen4, Shaobin Chen4, Xue Su1, Juan Ji1, Wanting Deng1, Xiang Li1, Shiyue Qiu1, Ruijing Yan1, Zexin Xu1, Yuan Wang1, Yuanning Guo1, Jiancheng Cui2, Shanshan Zhuang4, Huan Yu2, Qi Zheng2, Moshe Marom5, Sitong Sheng6, Guoqiang Zhang7, Songnian Hu7, Ruiqiang Li2, Min Su8. 1. Institute of Clinical Pathology, Department of Pathology, Shantou University Medical College, Shantou, Guangdong, China. 2. Novogene Co, Ltd, Beijing, China. 3. Institute of Clinical Pathology, Department of Pathology, Shantou University Medical College, Shantou, Guangdong, China; Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. 4. Cancer Hospital, Shantou University Medical College, Shantou, Guangdong, China. 5. Guangdong Technion-Israel Institute of Technology, Shantou, Guangdong, China. 6. HYK High-Throughput Biotechnology Institute, Software Park, Shenzhen, China. 7. Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China. 8. Institute of Clinical Pathology, Department of Pathology, Shantou University Medical College, Shantou, Guangdong, China. Electronic address: minsu@stu.edu.cn.
Abstract
BACKGROUND & AIMS: Esophageal squamous cell carcinoma (ESCC) is the most common subtype of esophageal cancer. Little is known about the genetic changes that occur in esophageal cells during the development of ESCC. We performed next-generation sequence analyses of esophageal nontumor, intraepithelial neoplasia (IEN), and ESCC tissues from the same patients to track genetic changes during tumor development. METHODS: We performed whole-genome, whole-exome, or targeted sequence analyses of 227 esophageal tissue samples from 70 patients with ESCC undergoing resection at Shantou University Medical College in China from 2012 through 2015 (no patients had received chemotherapy or radiation therapy); we analyzed normal tissues, tissues with simple hyperplasia, dysplastic tissues (IEN), and ESCC tissues collected from different regions of the esophagus at the same time. We also obtained 1191 nontumor esophageal biopsy specimens from the Chaoshan region (a high-risk region for ESCC) of China (a high-risk region for ESCC) and performed immunohistochemical and histologic analyses to detect inflammation. RESULTS: IEN and ESCC tissues had similar mutations and copy number alterations, at similar frequencies; these differed from mutations detected in tissues with simple hyperplasia. IEN tissues had mutations associated with apolipoprotein B messenger RNA editing enzyme, catalytic polypeptide-like-mediated mutagenesis (a DNA damage mutational signature). Genetic analyses indicated that most ESCCs were formed from early stage IEN clones. Trunk mutations (mutations shared by >10% of paired IEN and ESCC tissues) were in genes that regulate DNA repair and cell apoptosis, proliferation and adhesion. Mutations in TP53 and CDKN2A and copy number alterations in 11q (contains CCND1), 3q (contains SOX2), 2q (contains NFE2L2), and 9p (contains CDKN2A) were considered to be trunk variants; these were dominant mutations detected at high frequencies in clones of paired IEN and ESCC samples. In the esophageal biopsy samples from high-risk individuals (residing in the Chaoshan region), 68.9% had an evidence of chronic inflammation; the level of inflammation was correlated with atypical cell structures and markers of DNA damage. CONCLUSIONS: We analyzed mutations and gene copy number changes in nontumor, IEN, and ESCC samples, collected from 70 patients. IEN and ESCCs each had similar mutations and markers of genomic instability, including apolipoprotein B messenger RNA editing enzyme, catalytic polypeptide-like. Genomic changes observed in precancerous lesions might be used to identify patients at risk for ESCC.
BACKGROUND & AIMS:Esophageal squamous cell carcinoma (ESCC) is the most common subtype of esophageal cancer. Little is known about the genetic changes that occur in esophageal cells during the development of ESCC. We performed next-generation sequence analyses of esophageal nontumor, intraepithelial neoplasia (IEN), and ESCC tissues from the same patients to track genetic changes during tumor development. METHODS: We performed whole-genome, whole-exome, or targeted sequence analyses of 227 esophageal tissue samples from 70 patients with ESCC undergoing resection at Shantou University Medical College in China from 2012 through 2015 (no patients had received chemotherapy or radiation therapy); we analyzed normal tissues, tissues with simple hyperplasia, dysplastic tissues (IEN), and ESCC tissues collected from different regions of the esophagus at the same time. We also obtained 1191 nontumor esophageal biopsy specimens from the Chaoshan region (a high-risk region for ESCC) of China (a high-risk region for ESCC) and performed immunohistochemical and histologic analyses to detect inflammation. RESULTS: IEN and ESCC tissues had similar mutations and copy number alterations, at similar frequencies; these differed from mutations detected in tissues with simple hyperplasia. IEN tissues had mutations associated with apolipoprotein B messenger RNA editing enzyme, catalytic polypeptide-like-mediated mutagenesis (a DNA damage mutational signature). Genetic analyses indicated that most ESCCs were formed from early stage IEN clones. Trunk mutations (mutations shared by >10% of paired IEN and ESCC tissues) were in genes that regulate DNA repair and cell apoptosis, proliferation and adhesion. Mutations in TP53 and CDKN2A and copy number alterations in 11q (contains CCND1), 3q (contains SOX2), 2q (contains NFE2L2), and 9p (contains CDKN2A) were considered to be trunk variants; these were dominant mutations detected at high frequencies in clones of paired IEN and ESCC samples. In the esophageal biopsy samples from high-risk individuals (residing in the Chaoshan region), 68.9% had an evidence of chronic inflammation; the level of inflammation was correlated with atypical cell structures and markers of DNA damage. CONCLUSIONS: We analyzed mutations and gene copy number changes in nontumor, IEN, and ESCC samples, collected from 70 patients. IEN and ESCCs each had similar mutations and markers of genomic instability, including apolipoprotein B messenger RNA editing enzyme, catalytic polypeptide-like. Genomic changes observed in precancerous lesions might be used to identify patients at risk for ESCC.
Authors: Sarah Moody; Sergey Senkin; S M Ashiqul Islam; Jingwei Wang; Dariush Nasrollahzadeh; Ricardo Cortez Cardoso Penha; Stephen Fitzgerald; Erik N Bergstrom; Joshua Atkins; Yudou He; Azhar Khandekar; Karl Smith-Byrne; Christine Carreira; Valerie Gaborieau; Calli Latimer; Emily Thomas; Irina Abnizova; Pauline E Bucciarelli; David Jones; Jon W Teague; Behnoush Abedi-Ardekani; Stefano Serra; Jean-Yves Scoazec; Hiva Saffar; Farid Azmoudeh-Ardalan; Masoud Sotoudeh; Arash Nikmanesh; Hossein Poustchi; Ahmadreza Niavarani; Samad Gharavi; Michael Eden; Paul Richman; Lia S Campos; Rebecca C Fitzgerald; Luis Felipe Ribeiro; Sheila Coelho Soares-Lima; Charles Dzamalala; Blandina Theophil Mmbaga; Tatsuhiro Shibata; Diana Menya; Alisa M Goldstein; Nan Hu; Reza Malekzadeh; Abdolreza Fazel; Valerie McCormack; James McKay; Sandra Perdomo; Ghislaine Scelo; Estelle Chanudet; Laura Humphreys; Ludmil B Alexandrov; Paul Brennan; Michael R Stratton Journal: Nat Genet Date: 2021-10-18 Impact factor: 38.330
Authors: Shaohua Ma; Chorlada Paiboonrungruan; Tiansheng Yan; Kevin P Williams; M Ben Major; Xiaoxin Luke Chen Journal: Ann N Y Acad Sci Date: 2018-05-11 Impact factor: 5.691
Authors: Uma M Sachdeva; Masataka Shimonosono; Samuel Flashner; Ricardo Cruz-Acuña; Joel T Gabre; Hiroshi Nakagawa Journal: Cancer Lett Date: 2021-04-07 Impact factor: 9.756